ArticleParticle and fibre toxicology2019
Silver nanoparticles promote procoagulant activity of red blood cells: a potential risk of thrombosis in susceptible population.
Article in Particle and fibre toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 68 citations in OpenAlex.
- A cohort study on inflammatory response and coagulation function changes in women with silver clip or silk ligation sterilisation.Annals of medicine · 2026Article
- Quercetin mitigates size-dependent oxidative and metabolic toxicity of citrate-coated silver nanoparticles in human erythrocytes.Archives of toxicology · 2026Article
- Hemocompatibility of Carbosilane Dendrimers as a Therapeutic siRNA Delivery System across Blood-Brain Barrier.ACS applied materials & interfaces · 2026Article
- Cardiovascular Toxicity of Metal-Based Nanoparticles.International journal of molecular sciences · 2025Review
- Initiation of Progressive Morphological Transition Towards an Echino-Stomato-Spherocytic Phenotype by Phosphatidylserine Externalization and Its Implication in Thrombosis.International journal of molecular sciences · 2025Article
- Biomedical application of TiOCell biology and toxicology · 2024Article
- Antibiofilm and antithrombotic hydrogel coating based on superhydrophilic zwitterionic carboxymethyl chitosan for blood-contacting devices.Bioactive materials · 2024Article
- Implementation of Silver Nanoparticles Green Synthesized with Leaf Extract ofCurrent pharmaceutical biotechnology · 2024Article
- Evaluating the impact of cell-penetrating motif position on the cellular uptake of magnetite nanoparticles.Frontiers in bioengineering and biotechnology · 2024Article
- Nanosilver: An Old Antibacterial Agent with Great Promise in the Fight against Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- Application of Inorganic Nanomaterials in Cultural Heritage Conservation, Risk of Toxicity, and Preventive Measures.Nanomaterials (Basel, Switzerland) · 2023Review
- Impact of Plasmonic Nanoparticles on Poikilocytosis and Microrheological Properties of Erythrocytes.Pharmaceutics · 2023Article
- Article
- Amine-modified nanoplastics promote the procoagulant activation of isolated human red blood cells and thrombus formation in rats.Particle and fibre toxicology · 2022Article
- Bell Shape Curves of Hemolysis Induced by Silver Nanoparticles: Review and Experimental Assay.Nanomaterials (Basel, Switzerland) · 2022Review
- Mass Cytometry Exploration of Immunomodulatory Responses of Human Immune Cells Exposed to Silver Nanoparticles.Pharmaceutics · 2022Article
- Exacerbation of Thrombotic Responses to Silver Nanoparticles in Hypertensive Mouse Model.Oxidative medicine and cellular longevity · 2022Article
- Titanium dioxide nanoparticles enhance thrombosis through triggering the phosphatidylserine exposure and procoagulant activation of red blood cells.Particle and fibre toxicology · 2021Article
- Hemolysis of Human Erythrocytes by Argovit™ AgNPs from Healthy and Diabetic Donors: An In Vitro Study.Materials (Basel, Switzerland) · 2021Article
- Dose-dependent efficacy of antioxidant nanoparticles on red blood cells storage.Journal of education and health promotion · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundSilver nanoparticles (AgNP) are widely used in medical practices owing to their distinct antibacterial, antiviral and anticancer activities. However, with increasing use of AgNP, concerns over its potential toxicity are also escalating. Here, we demonstrated the potential thrombotic effect of AgNP which was mediated by the procoagulant activity of red blood cells (RBCs).
resultsIn freshly isolated human RBCs, AgNP, but not silver microparticles (AgMP), elicited morphological changes, phosphatidylserine (PS) exposure and microvesicles (MV) generation, the key indicators of procoagulant activity in RBCs at concentration ranges (≤ 100 μg/mL) that were free of significant hemolysis. In line with this, AgNP potentiated thrombin generation and adherence of RBCs to endothelial cells, while AgMP did not. Oxidative stress, intracellular calcium increase and ATP depletion were found to underlie the procoagulant effects of AgNP, which led to altered activity of membrane aminophospholipid translocases. These in vitro findings were well reproduced in rat in vivo, where intravenously exposure to AgNP promoted venous thrombosis significantly. Of note, RBCs isolated from cancer patients, who inherently convey the risk of thrombogenesis, were more sensitive to the procoagulant effects of AgNP. In addition, AgNP significantly potentiated the procoagulant effects of a chemotherapeutic drug, paclitaxel.
conclusionCollectively, these results suggest that AgNP may have prothrombotic risks by promoting procoagulant activity of RBCs and caution shall be taken for its use in the population sensitive to thrombosis like cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.